Ophthalmic solutions comprising difluoroprostaglandin f2 alpha

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/5575 (2006.01) A61K 9/00 (2006.01) A61K 9/08 (2006.01) A61K 47/10 (2006.01) A61K 47/18 (2006.01) A61K 47/34 (2006.01) A61K 47/44 (2006.01) A61P 27/02 (2006.01) A61K 47/26 (2006.01)

Patent

CA 2422031

An object of the present invention is to formulate prostaglandin derivatives which are hardly soluble in water and liable to be adsorbed to a resinous container and prostaglandin derivatives which are liable to decompose when dissolved in water in ophthalmic solutions. Solubility of the prostaglandin derivatives in water is improved and the adsorption thereof to the resinous container can be remarkably inhibited by adding a nonionic surfactant such as polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 to the ophthalmic solutions. The decomposition of the prostaglandin derivatives can be remarkably inhibited by adding an antioxidant such as disodium ethylenediaminetetraacetate or dibutylhydroxytoluene.

L'invention concerne des procédés de production de préparations de collyre renfermant des dérivés de prostaglandine peu solubles dans l'eau et susceptibles d'être adsorbés par des contenants en résine ou des dérivés de prostaglandine susceptibles de se décomposer lorsqu'ils sont dissous dans l'eau. La solubilité des dérivés de prostaglandine dans l'eau peut être améliorée et l'adsorption de ceux-ci par des contenants en résine peut être remarquablement inhibée par l'ajout de tensioactifs non ioniques, tels que du poylsorbate 80 ou de l'huile de ricin durcie au polyoxyéthylène 60, aux collyres. De plus, la décomposition des dérivés de prostaglandine peut être remarquablement inhibée par l'ajout d'agents anti-oxydants, tels que du éthylènediaminétetracétate disodique ou dudibutylhydroxytoluène.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Ophthalmic solutions comprising difluoroprostaglandin f2 alpha does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ophthalmic solutions comprising difluoroprostaglandin f2 alpha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic solutions comprising difluoroprostaglandin f2 alpha will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1676014

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.